Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tisagenlecleucel trial in first-line high-risk pediatric and young adult B-cell acute lymphoblastic leukemia with MRD positivity after consolidation
2017-002116-14Phase 2Active
- Sponsor
- Novartis
- Start
- Jul 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Primary endpoint: 4-year overall survival rate. Started Jul 2018; status: active.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2017-002116-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002116-14.